Patents by Inventor YANGQING HUANG
YANGQING HUANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150425Abstract: A GIP and GLP-1 dual receptor agonist, a pharmaceutical composition, and the use. In particular, the present application relates to a compound represented by formula I, a pharmaceutical composition comprising the compound, and the use of the compound as a GIP and GLP-1 dual receptor agonist in the field of medicine. The compound represented by formula I exhibits excellent GIPR and GLP-1R agonist activity and excellent pharmaceutical activity in reducing blood sugar and controlling body weight, is a therapeutic drug having a clinical application prospect, and can be used for preventing and treating diseases such as diabetes, diabetes complications, obesity, or obesity complications.Type: ApplicationFiled: December 14, 2023Publication date: May 9, 2024Applicants: BrightGene Bio-Medical Technology Co., Ltd., BRIGHTGENE PHARMACEUTICAL (SUZHOU) CO. LTD.Inventors: Jiandong YUAN, Yunsong SONG, Wenteng ZHEN, Yue CAI, Jianing GU, Yangqing HUANG
-
Publication number: 20220096644Abstract: Disclosed is a class of multi-branched drug conjugates capable of specifically targeting CD44. The class of compounds specifically binds to CD44, and may target tumor cells and tissues having high expression of CD44, so that the concentration of the conjugate in a target tissue is high, the clinical treatment effect thereof is improved, and toxicity is reduced. The compound of the present invention is suitable for treating all tumors having high expression of CD44, comprising but not limited to gastric cancer, pancreatic cancer, small cell lung cancer, colon cancer, breast cancer, lung adenocarcinoma, liver cancer, nasopharyngeal carcinoma, malignant glioma, lymphoma, renal carcinoma, ovarian cancer, head and neck cancer, squamous cell carcinoma, and the like.Type: ApplicationFiled: February 17, 2020Publication date: March 31, 2022Inventors: Jiandong Yuan, Yangqing Huang, Yunsong Song
-
Patent number: 11191843Abstract: A multi-branched drug conjugate of formula (I) or a pharmaceutically acceptable salt thereof. In the formula, R is an organic center, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is an active agent, and q is any integer between 3 and 8. The symbol “*” in L represents a junction point of the multivalent linker L and the targeting molecule T, “#” represents a junction point of the multivalent linker L and the active agent D, and “%” represents a junction point of the multivalent linker L and POLY. 1 is any integer between 2 and 20, and m and n are each an integer between 0 and 10. T is iRGD, cRGD, tLyp-1, Lyp-1, RPARPAR, Angiopep2, or GE11. D is a camptothecin drug.Type: GrantFiled: April 19, 2018Date of Patent: December 7, 2021Assignee: BrightGene Bio-Medical Technology Co., Ltd.Inventors: Jiandong Yuan, Yangqing Huang, Yunsong Song, Haifeng Ding
-
Patent number: 11179467Abstract: Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.Type: GrantFiled: September 13, 2016Date of Patent: November 23, 2021Assignee: BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.Inventors: Jiandong Yuan, Yangqing Huang, Yunsong Song, Fang Yuan
-
Patent number: 10913756Abstract: The present disclosure involves a composition enriched in compound 61501b, wherein the compound 61501b has a purity of not less than 90% or more. The composition has a significant advantage in preparing a high-purity compound Sp-1. In addition, the present disclosure also provides a preparation method of the composition enriched in compound 61501b. The method adopts a crystallization technique to perform separation and purification, has a simple and convenient operation and good reproducibility, and therefore the compound 61501b in the prepared composition has high purity and quality. Further, the present disclosure also involves a novel crystal form of compound 61501b.Type: GrantFiled: December 6, 2019Date of Patent: February 9, 2021Assignee: BrightGene Bio-Medical Technology Co., Ltd.Inventors: Jiandong Yuan, Yangqing Huang, Linfeng Miao, Jianing Gu, Chaohua Liang, Zhengye Wang, Zhanli Sun
-
Publication number: 20210008218Abstract: A multi-branched dnig conjugate of formula (I) or a pharmaceutically acceptable salt thereof. In the formula, R is an organic center, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is an active agent, and q is any integer between 3 and 8. The symbol “*” in L represents a junction point of the multivalent linker L and the targeting molecule T, “#” represents a junction point of the multivalent linker L and the active agent D, and “%” represents a junction point of the multivalent linker L and POLY. 1 is any integer between 2 and 20, and m and n are each an integer between 0 and 10. T is iRGD, cRGD, tLyp-1, Lyp-1, RPARPAR, Angiopep2, or GE11. D is a camptothecin drug.Type: ApplicationFiled: April 19, 2018Publication date: January 14, 2021Inventors: Jiandong Yuan, Yangqing Huang, Yunsong Song, Haifeng Ding
-
Patent number: 10869863Abstract: Disclosed is a multi-arm targeting drug conjugate modified by a water-soluble polymer; the drug conjugate has the structural formula of (III). In formula (III), R is an organic core, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is a camptothecin-based drug, and q is any integer between 3 and 8. The drug conjugate may improve the poor water solubility, high toxicity and low bioavailability of camptothecin-based drugs.Type: GrantFiled: May 15, 2017Date of Patent: December 22, 2020Assignee: BrightGene Bio-Medical Technology Co., Ltd.Inventors: Jiandong Yuan, Yangqing Huang, Yunsong Song, Fang Yuan
-
Patent number: 10689413Abstract: Provided is a preparation method of a composition enriched in compound Sp-1. The method performs isomer separation on a reaction product from the first step, and then performs a two-step chemical synthesis, so as to prepare a composition comprising high-purity compound Sp-1, wherein the HPLC purity of the single isomer Sp-1 is 90% or more. Provided is a composition enriched in compound Sp-1. The composition has an inhibitory effect on tumor cell proliferation in vitro significantly higher than that of NUC-1031 and compound Rp-1. Also provided are the use of the composition, and a pharmaceutical composition comprising the composition and at least one pharmaceutically acceptable excipient.Type: GrantFiled: September 13, 2016Date of Patent: June 23, 2020Assignee: BrightGene Bio-Medical Technology Co., Ltd.Inventors: Jiandong Yuan, Yangqing Huang, Linfeng Miao, Jianing Gu, Chaohua Liang, Zhengye Wang, Zhanli Sun
-
Publication number: 20200190125Abstract: The present disclosure involves a composition enriched in compound 61501b, wherein the compound 61501b has a purity of not less than 90% or more. The composition has a significant advantage in preparing a high-purity compound Sp-1. In addition, the present disclosure also provides a preparation method of the composition enriched in compound 61501b. The method adopts a crystallization technique to perform separation and purification, has a simple and convenient operation and good reproducibility, and therefore the compound 61501b in the prepared composition has high purity and quality. Further, the present disclosure also involves a novel crystal form of compound 61501b.Type: ApplicationFiled: December 6, 2019Publication date: June 18, 2020Inventors: Jiandong Yuan, Yangqing Huang, Linfeng Miao, Jianing Gu, Chaohua Liang, Zhengye Wang, Zhanli Sun
-
Publication number: 20200101162Abstract: Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.Type: ApplicationFiled: September 13, 2016Publication date: April 2, 2020Applicant: BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.Inventors: Jiandong YUAN, Yangqing HUANG, Yunsong SONG, Fang YUAN
-
Patent number: 10538541Abstract: The present disclosure involves a composition enriched in compound 61501b, wherein the compound 61501b has a purity of not less than 90% or more. The composition has a significant advantage in preparing a high-purity compound Sp-1. In addition, the present disclosure also provides a preparation method of the composition enriched in compound 61501b. The method adopts a crystallization technique to perform separation and purification, has a simple and convenient operation and good reproducibility, and therefore the compound 61501b in the prepared composition has high purity and quality. Further, the present disclosure also involves a novel crystal form of compound 61501b.Type: GrantFiled: September 13, 2016Date of Patent: January 21, 2020Assignee: BrightGene Bio-Medical Technology Co., Ltd.Inventors: Jiandong Yuan, Yangqing Huang, Linfeng Miao, Jianing Gu, Chaohua Liang, Zhengye Wang, Zhanli Sun
-
Publication number: 20200000797Abstract: Disclosed is a multi-arm targeting drug conjugate modified by a water-soluble polymer; the drug conjugate has the structural formula of (III). In formula (III), R is an organic core, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is a camptothecin-based drug, and q is any integer between 3 and 8. The drug conjugate may improve the poor water solubility, high toxicity and low bioavailability of camptothecin-based drugs.Type: ApplicationFiled: May 15, 2017Publication date: January 2, 2020Inventors: Jiandong Yuan, Yangqing Huang, Yunsong Song, Fang Yuan
-
Patent number: 10292940Abstract: Disclosed are a hyaluronic acid-based amphiphilic polymer, preparation method and application thereof. A main chain of the amphiphilic polymer is a hydrophilic hyaluronic acid and can be employed in active targeting, and a side chain thereof is a hydrophobic group represented by Formula (1). The amphiphilic polymer can carry a small molecule anticancer drug. Polymer nanoparticles are obtained via chemical crosslinking, such that the nanoparticles are not readily dissociated outside a cell or in blood, thus ensuring the stability of a drug encapsulated by the nanoparticles. Upon arriving at a tumor tissue, the hyaluronic acid on a surface of the nanoparticle can immediately combine with a CD44 receptor on a surface of a tumor cell, and effectively enter the tumor cell via endocytosis mediated by the receptor, and then quickly de-crosslink to be dissociated.Type: GrantFiled: January 4, 2016Date of Patent: May 21, 2019Assignee: BrightGene Bio-Medical Technology Co., Ltd.Inventors: Zhiyuan Zhong, Yinan Zhong, Fenghua Meng, Jiandong Yuan, Yangqing Huang, Jianwen Chi
-
Publication number: 20180244710Abstract: Provided is a preparation method of a composition enriched in compound Sp-1. The method performs isomer separation on a reaction product from the first step, and then performs a two-step chemical synthesis, so as to prepare a composition comprising high-purity compound Sp-1, wherein the HPLC purity of the single isomer Sp-1 is 90% or more. Provided is a composition enriched in compound Sp-1. The composition has an inhibitory effect on tumor cell proliferation in vitro significantly higher than that of NUC-1031 and compound Rp-1. Also provided are the use of the composition, and a pharmaceutical composition comprising the composition and at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: September 13, 2016Publication date: August 30, 2018Inventors: Jiandong Yuan, Yangqing Huang, Lingfeng Miao, Jianing Gu, Chaohua Liang, Zhengye Wang, Zhanli Sun
-
Publication number: 20180244701Abstract: The present disclosure involves a composition enriched in compound 61501b, wherein the compound 61501b has a purity of not less than 90% or more. The composition has a significant advantage in preparing a high-purity compound Sp-1. In addition, the present disclosure also provides a preparation method of the composition enriched in compound 61501b. The method adopts a crystallization technique to perform separation and purification, has a simple and convenient operation and good reproducibility, and therefore the compound 61501b in the prepared composition has high purity and quality. Further, the present disclosure also involves a novel crystal form of compound 61501b.Type: ApplicationFiled: September 13, 2016Publication date: August 30, 2018Inventors: Jiandong Yuan, Yangqing Huang, Lingfeng Miao, Jianing Gu, Chaohua Liang, Zhengye Wang, Zhanli Sun
-
Publication number: 20180237466Abstract: Provided in the present disclosure are a novel preparation method of nucleoside phosphoramidate prodrugs and the intermediates thereof. In particular, the method is adopted to perform isomer separation on the reaction product from a first step and then perform a two-step chemical synthesis, so as to prepare a high-purity compound Sp-1. The method has simple and convenient operation and low cost. The prepared resulting single isomer Sp-1 has high purity, and the HPLC purity thereof is 95% or more, and further, 99% or more. The method is suitable for industrial production and can satisfy the need of clinical study. Further, also provided in the present disclosure are a key intermediate phosphorus reagent for preparing the high-purity compound Sp-1 and the preparation method thereof.Type: ApplicationFiled: September 13, 2016Publication date: August 23, 2018Inventors: Jiandong Yuan, Yangqing Huang, Lingfeng Miao, Jianing Gu, Chaohua Liang, Zhengye Wang, Zhanli Sun
-
Publication number: 20180092858Abstract: Disclosed are a hyaluronic acid-based amphiphilic polymer, preparation method and application thereof. A main chain of the amphiphilic polymer is a hydrophilic hyaluronic acid and can be employed in active targeting, and a side chain thereof is a hydrophobic group represented by Formula (1). The amphiphilic polymer can carry a small molecule anticancer drug. Polymer nanoparticles are obtained via chemical crosslinking, such that the nanoparticles are not readily dissociated outside a cell or in blood, thus ensuring the stability of a drug encapsulated by the nanoparticles. Upon arriving at a tumor tissue, the hyaluronic acid on a surface of the nanoparticle can immediately combine with a CD44 receptor on a surface of a tumor cell, and effectively enter the tumor cell via endocytosis mediated by the receptor, and then quickly de-crosslink to be dissociated.Type: ApplicationFiled: January 4, 2016Publication date: April 5, 2018Inventors: Zhiyuan Zhong, Yinan Zhong, Fenghua Meng, Jiandong Yuan, Yangqing Huang, Jianwen Chi
-
Patent number: 9602656Abstract: Various embodiments provide methods, apparatus, and systems for providing caller ID. In an exemplary method implemented on a caller device, a portrait file to be used as a caller ID is created, and sent to a portrait distribution system (PDS) on a server via an IP network. A distribution policy corresponding to the portrait file is generated, and sent to a policy control system (PCS) on the server via the IP network, to cause the PCS to perform a selective distribution process. The selective distribution process includes selecting a callee device by using the distribution policy, generating a notification, and sending the notification to the callee device, such that the callee device downloads the portrait file from the PDS via the IP network according to the notification and executes the portrait file as the caller ID when the caller device calls the callee device.Type: GrantFiled: April 20, 2014Date of Patent: March 21, 2017Assignee: IHANDY INC.Inventors: Yangqing Huang, Jinfei Zhang
-
Publication number: 20150304490Abstract: Various embodiments provide methods, apparatus, and systems for providing caller ID. In an exemplary method implemented on a caller device, a portrait file to be used as a caller ID is created, and sent to a portrait distribution system (PDS) on a server via an IP network. A distribution policy corresponding to the portrait file is generated, and sent to a policy control system (PCS) on the server via the IP network, to cause the PCS to perform a selective distribution process. The selective distribution process includes selecting a callee device by using the distribution policy, generating a notification, and sending the notification to the callee device, such that the callee device downloads the portrait file from the PDS via the IP network according to the notification and executes the portrait file as the caller ID when the caller device calls the callee device.Type: ApplicationFiled: April 20, 2014Publication date: October 22, 2015Applicant: iHandy Inc.Inventors: YANGQING HUANG, JINFEI ZHANG